New Delhi, Dec 30, 2014 – Drug major Lupin has received US health regulator’s approval to market a generic version of ViiV Healthcare’s Epivir Tablets, used in treating HIV infection, in the American market.
The Mumbai-based firm has received final approval from the US Food and Drug Administration ( USFDA) for itsLamivudine tablets in strengths of 150 mg and 300 mg, Lupin Ltd said in a statement.
Lupin Pharmaceuticals Inc (LPI), the company’s US subsidiary, would commence marketing the product shortly, it added.
Epivir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.
According to IMS MAT September 2014 sales data, Epivir tablets had annual US sales of USD 39.7 million.
Lupin shares were trading at Rs 1,401 apiece on the BSE, down 0.12 per cent from their previous close. PTI
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…